John Kirkwood
John Kirkwood
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma | Unresectable Cutaneous Melanoma | Not yet recruiting | Phase 1 / Phase 2 | 2026-07-13 | NCT07631325 | |
| Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, central nervous system malformation, hereditary disease, hereditary neoplastic syndrome, hereditary sensory and autonomic neuropathy, inherited neurodegenerative disorder, melanocytic neoplasm, melanocytic nevus, melanoma, melanoma, cutaneous malignant, susceptibility to, 2, neoplasm, nervous system disorder, neurodegenerative disease, neuroendocrine neoplasm, neuromuscular disease, peripheral nervous system disorder, polyneuropathy, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Not stated | 2026-01-26 | NCT06599619 | |
| Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma | Locally Advanced Melanoma | Recruiting | Not stated | 2025-11-26 | NCT07223411 |